A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
Introduction: Patients with early-stage hormone receptor positive, human epidermal growth factor receptor-2 (HER2) negative invasive breast cancer with 1-3 positive lymph nodes (N1) often undergo surgical excisions followed by adjuvant chemotherapy (ACT). Many patients have no benefit from ACT and receive unnecessary, costly treatment often associated with short- and long-term adverse events (AEs). Gene expression profiling (GEP) assays, such as the 21-gene assay (i.e., the Oncotype DX assay), can identify patients at higher risk for recurrence who may benefit from ACT. However, the budgetary... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Text |
Erscheinungsdatum: | 2024 |
Schlagwörter: | Medicine / Pharmacology / Cancer / Science Policy / Biological Sciences not elsewhere classified / 21-gene / gene expression profiling / early stage / hormone receptor / human epidermal growth factor receptor 2 / breast cancer / lymph node positive / adjuvant chemotherapy / cost-consequence analysis / A11 / A1 / A / C21 / C2 / C / C51 / C5 |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-28785131 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.6084/m9.figshare.25334767.v1 |